Absolutely! You are helping accelerate cancer research and drug development by doing this. Almost all of the companies that provide these tests partner with bio-pharma clients throughout each stage of drug research and development, from target discovery to commercial launch. We need to develop better drugs, faster. Broad testing of patients would make more data available to bio-pharma companies, accelerating the pace of research and the identification
...Read More
of more patients for clinical trials. Ultimately, that could lead to the development of more effective — and cheaper — targeted drugs. It’s a virtuous cycle. In the future, more patients who receive a genomic diagnostic test like this would have a greater choice of approved treatment options for their specific cancer. We need to accelerate the development of treatments that provide the optimal outcome for every patient diagnosed with advanced cancer.
Read Less